SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	Idress of Reporti	0	2. Date of Event Requiring Statement (Month/Day/Year) 03/28/2018	ment CHIMERIX INC [CMRX]						
(Street) DURHAM	DIAN PARKW	(Middle) /AY, SUITE 100 27713			tionship of Reporting Per all applicable) Director Officer (give title below)	rson(s) to Issue 10% Own Other (spe below)	er ecify	(Month/Day/Year) 6. Individual or Jo Applicable Line) X Form filed	Date of Original Filed int/Group Filing (Check by One Reporting Person by More than One Person	
(City)	(State)	(Zip)	Table I Non Dor	ivativo S	ecurities Beneficia					
1. Title of Security (Instr. 4)				2. Amou	int of Securities ially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)		4. Nature of Indirect Beneficial Ownership (Instr. 5)		
Common Stock					2,776,093	Ι		See footnotes ⁽¹⁾⁽²⁾		
Common Stock					531,861	Ι		See footnotes ⁽²⁾⁽³⁾		
Common Stock					3,446	Ι		See footnotes ⁽²⁾⁽⁴⁾		
Common Stock					67,523	D				
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)										
1. Title of Derivative Security (Instr. 4)			2. Date Exercisable Expiration Date (Month/Day/Year)		itle and Amount of Secu erlying Derivative Secu		4. Convers or Exerc Price of Derivativ Security	ise Form: Direct (D) /e or Indirect	6. Nature of Indirect Beneficial Ownership (Instr. 5)	

Explanation of Responses:

1. The securities are held as follows: 829,046 shares of common stock held by Sanderling Venture Partners V, L.P., 233,134 shares of common stock held by Sanderling V Biomedical, L.P., 155,143 shares of common stock held by Sanderling V Limited Partnership, 138,046 shares of common stock held by Sanderling V Beteiligungs GmbH & Co. KG, 199,853 shares of common stock held by Sanderling V Biomedical Co-Investment Fund, L.P., 329,682 shares of common stock held by Sanderling Venture Partners V Co-Investment Fund, L.P. and 891,189 shares of common stock held by Sanderling V Strategic Exit Fund, L.P. (collectively, the Sanderling V Shares).

Title

Expiration

Date

2. The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling V Shares, the Sanderling VI Shares and the Middleton-McNeil Retirement Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

3. The securities are held as follows: 498,046 shares of common stock held by Sanderling Venture Partners VI Co-Investment Fund, L.P., 15,431 shares of common stock held by Sanderling VI Beteiligungs GmbH & Co. KG and 18,384 shares of common stock held by Sanderling VI Limited Partnership (collectively, the Sanderling VI Shares).

4. The securities are held as follows: 3,446 shares of common stock held by the Middleton-McNeil Retirement Trust.

Remarks:

/s/ Michael Alrutz, Attorney-

Number

Shares

of

04/06/2018

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Date

Exercisable

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

in-Fact